Page last updated: 2024-08-18

pyrroles and erdafitinib

pyrroles has been researched along with erdafitinib in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	5 (100.00)	2.80

Authors

Authors	Studies
Babiker, HM; Chandana, SR; Mahadevan, D	1
Bossaer, JB; Weaver, A	1
Al-Obaidy, KI; Cheng, L	1
Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A	1
Javle, M; King, G	1

Reviews

4 review(s) available for pyrroles and erdafitinib

Article	Year
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:12 Topics: Animals; Antineoplastic Agents; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, Fibroblast Growth Factor	2020
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:3 Topics: Bile Duct Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3	2021
Fibroblast growth factor receptor ( Journal of clinical pathology, 2021, Volume: 74, Issue:8 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium	2021
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Current oncology reports, 2021, 07-16, Volume: 23, Issue:9 Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Mutation; Phenylurea Compounds; Precision Medicine; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction	2021

Other Studies

1 other study(ies) available for pyrroles and erdafitinib

Article	Year
FGFR alterations in urothelial carcinoma: Picking the right target. Bulletin du cancer, 2021, Volume: 108, Issue:6 Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms	2021

Article

Year

FGFR alterations in urothelial carcinoma: Picking the right target.

Bulletin du cancer, 2021, Volume: 108, Issue:6

Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms

2021